Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheldon Preskorn

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 19, 2006
Detrimental antidepressant drug-drug interactions: are they clinically relevant?Sheldon Preskorn, Steve Werder
Current Opinion in Pharmacology|February 26, 2014
Clinical pharmacology in the development of new antidepressants: the challengesRobert C Alexander, Sheldon Preskorn
Journal of Psychiatric Practice|September 9, 2015
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1Sheldon Preskorn, Alexandra Flynn, Matthew Macaluso
Journal of Psychiatric Practice|January 28, 2016
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept StudiesMatthew Macaluso, Alexandra Flynn, Sheldon Preskorn
International Clinical Psychopharmacology|February 25, 2005
D2-blockade and possible ziprasidone-induced galactorrheaMohamed Ramadan, Ahsan Khan, Sheldon Preskorn
Journal of Psychiatric Practice|April 29, 2016
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report DataMatthew Macaluso, Alexandra Flynn, Sheldon Preskorn
Journal of Clinical Psychopharmacology|January 2, 2013
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneSteven G Potkin, Sheldon Preskorn, Marla Hochfeld, et al.
Human Psychopharmacology|September 10, 2013
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesSheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, et al.
BMJ Open|February 24, 2012
Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trialJonathan Savitz, Sheldon Preskorn, T Kent Teague, et al.
Journal of Psychiatric Practice|March 19, 2015
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agentSheldon Preskorn, Matthew Macaluso, D O Vishaal Mehra, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 19, 2006
Detrimental antidepressant drug-drug interactions: are they clinically relevant?Sheldon Preskorn, Steve Werder
Current Opinion in Pharmacology|February 26, 2014
Clinical pharmacology in the development of new antidepressants: the challengesRobert C Alexander, Sheldon Preskorn
Journal of Psychiatric Practice|September 9, 2015
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1Sheldon Preskorn, Alexandra Flynn, Matthew Macaluso
Journal of Psychiatric Practice|January 28, 2016
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept StudiesMatthew Macaluso, Alexandra Flynn, Sheldon Preskorn
International Clinical Psychopharmacology|February 25, 2005
D2-blockade and possible ziprasidone-induced galactorrheaMohamed Ramadan, Ahsan Khan, Sheldon Preskorn
Journal of Psychiatric Practice|April 29, 2016
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report DataMatthew Macaluso, Alexandra Flynn, Sheldon Preskorn
Journal of Clinical Psychopharmacology|January 2, 2013
A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneSteven G Potkin, Sheldon Preskorn, Marla Hochfeld, et al.
Human Psychopharmacology|September 10, 2013
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesSheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, et al.
BMJ Open|February 24, 2012
Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trialJonathan Savitz, Sheldon Preskorn, T Kent Teague, et al.
Journal of Psychiatric Practice|March 19, 2015
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agentSheldon Preskorn, Matthew Macaluso, D O Vishaal Mehra, et al.
Pageof 2